Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Revista alergia México
versión On-line ISSN 2448-9190
Resumen
AGUILAR-HINOJOSA, Nadia Karina y SANCHEZ-TEC, Georgina. Quality of life in patients with allergic asthma on treatment with omalizumab. Rev. alerg. Méx. [online]. 2018, vol.65, n.4, pp.349-356. ISSN 2448-9190. https://doi.org/10.29262/ram.v65i4.382.
Background:
Omalizumab is a monoclonal antibody that controls severe allergic asthma symptoms and reduces exacerbations.
Objective:
To analyze quality of life and respiratory function improvement using the mini-AQLQ questionnaire and spirometry, with the use omalizumab as complementary therapy to a treatment with inhaled corticosteroids and long-acting beta 2 agonists.
Methods:
Of 30 patients with severe asthma (90 % of females, mean age, 49.1 years) the evolution of severe asthma diagnosis ranged from 1 to 24 years (average 8.3 years). All of them had at least one cutaneous or IgE-specific test that was positive to a usual aeroallergen, had total IgE determined and underwent spirometry. The mini-AQLQ questionnaire was applied and forced expiratory volume in 1 second (FEV1) was determined at baseline and at 52 weeks of omalizumab administration, the average dose of which was 550 mg, with biweekly or monthly administration.
Results:
There was statistically significant improvement (p = 0.013) in the mini-AQLQ after 52 weeks, with an overall score of 4.5, mainly in the emotional (p = 0.0073) and environmental dimensions (p = 0.00014). There were no significant changes in FEV1. Obesity was observed in 63 % of patients, and overweight in 26 %.
Conclusions:
Omalizumab improved patient quality of life, with no significant changes in FEV1, probably due to obesity.
Palabras llave : Allergic asthma; Omalizumab; Quality of life.